Acceleron Pharma (XLRN) Misses Q2 EPS by 9c

Acceleron Pharma (NASDAQ: XLRN) reported Q2 EPS of ($0.59), $0.09 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $3.77 million.

Cash, cash equivalents and investments as of June 30, 2016 were $262.7 million. As of December 31, 2015 the Company had cash, cash equivalents and investments of $136.0 million. The Company believes that existing cash, cash equivalents and investments will be sufficient to fund its projected operating requirements into the second half of 2019.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c